Remedent (REMI) Stock Price

Remedent Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue at Remedent has contracted by 10.5% per year over the past 19 years to 986,220.00 USD. Earnings per share have grown at 23.3% per year over the last 7 years. Remedent's net margin stands at -27.8%, up from -80.3% several years earlier. The stock trades about 250% above its 52-week low.

Remedent stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Remedent over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Remedent stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Remedent's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Remedent Stock Price History
DateRemedent Price
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/5/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/28/20250.00 USD
10/7/20250.00 USD
9/26/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Remedent Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
2.68 M USD
-1.22 M USD
961,486.64 USD
Jan 1, 2018
3.07 M USD
-35,359.01 USD
-62,162.94 USD
Jan 1, 2019
1.83 M USD
2.43 M USD
2.42 M USD
Jan 1, 2020
1.21 M USD
-954,064.60 USD
-972,756.40 USD
Jan 1, 2021
1.17 M USD
-36,689.01 USD
-185,722.46 USD
Jan 1, 2022
1.60 M USD
361,515.43 USD
-292,853.92 USD
Jan 1, 2023
863,819.00 USD
-283,030.00 USD
-1.49 M USD
Jan 1, 2024
986,220.00 USD
-122,890.00 USD
-274,446.00 USD

Remedent Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 27, 2026, 12:13 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2009201020112012201320142015201620172018201920202021202220232024
16.009.0014.0011.003.002.004.003.002.003.001.001.001.001.00––
100.00-43.7555.56-21.43-72.73-33.33100.00-25.00-33.3350.00-66.67–––––
56.2544.4464.2972.7333.3350.0050.0066.6750.0066.67100.00100.00100.00100.00––
9.004.009.008.001.001.002.002.001.002.001.001.001.001.001.001.00
-1.00-3.00––-2.00–––-1.00–2.00–––––
-6.25-33.33––-66.67–––-50.00–200.00–––––
-3.00-2.00-1.00–-1.00–––––2.00–––-1.00–
–-33.33-50.00–––––––––––––
20.5520.5820.0020.0020.0020.0020.0020.0020.0020.0020.0020.0020.0020.0020.0020.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Remedent generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Remedent retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Remedent's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Remedent has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Remedent's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Remedent stock margins

The Remedent margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Remedent. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Remedent.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
50.31 %
-45.41 %
35.84 %
Jan 1, 2018
66.00 %
-1.15 %
-2.02 %
Jan 1, 2019
63.57 %
132.85 %
132.74 %
Jan 1, 2020
69.73 %
-78.71 %
-80.26 %
Jan 1, 2021
56.18 %
-3.13 %
-15.84 %
Jan 1, 2022
74.38 %
22.55 %
-18.27 %
Jan 1, 2023
58.53 %
-32.76 %
-173.05 %
Jan 1, 2024
61.17 %
-12.46 %
-27.83 %

Remedent Stock Revenue, EBIT, Earnings per Share

The Remedent earnings per share therefore indicates how much revenue Remedent has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0.13 USD
-0.06 USD
0.05 USD
Jan 1, 2018
0.15 USD
-0.00 USD
-0.00 USD
Jan 1, 2019
0.09 USD
0.12 USD
0.12 USD
Jan 1, 2020
0.06 USD
-0.05 USD
-0.05 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.08 USD
0.02 USD
-0.01 USD
Jan 1, 2023
0.04 USD
-0.01 USD
-0.07 USD
Jan 1, 2024
0.05 USD
-0.01 USD
-0.01 USD

Remedent business model & stock analysis

Remedent Inc is a company specialized in the development, manufacturing, and marketing of innovative dental products. It was founded in 1997 by Jürgen Steenwelle and Philippe de Bergeyck, with its headquarters in Mariakerke, Belgium. The company started with the creation of the GlamSmile veneer system, which revolutionized aesthetic dentistry. Remedent expanded its product portfolio to include teeth whitening systems, dental implants, dental instruments, and dental software solutions. The company aims to revolutionize the dental market with innovative technologies and materials. Remedent works closely with dental professionals worldwide to ensure the highest quality standards. It has locations in Europe, the USA, and Asia. Partnership with dentists and clinics is a key aspect of Remedent's business model, offering training and certifications to ensure proper and effective use of their products. The company is focused on global market expansion through strategic acquisitions and mergers to grow its customer base and promote technological advancements. Remedent has achieved impressive growth and success in a highly competitive market, remaining a significant provider of dental products and pursuing a strong growth strategy.

Remedent SWOT Analysis

Strengths

Remedent Inc possesses several strengths that contribute to its success in the market. Firstly, the company has a strong reputation for providing high-quality dental products and services. This reputation is built on decades of experience and a commitment to excellence.

Another strength of Remedent Inc is its innovative product portfolio. The company continually invests in research and development, leading to the creation of cutting-edge dental technologies and solutions. This allows Remedent Inc to stay ahead of its competitors and cater to the evolving needs of dental professionals.

Weaknesses

Despite its strengths, Remedent Inc also faces certain weaknesses that need to be addressed. One significant weakness is its limited market presence outside of its home country. Expanding into international markets would expose the company to a broader customer base and potential growth opportunities.

Additionally, Remedent Inc heavily relies on a few key suppliers, which can pose a risk to the company's supply chain. Diversifying the supplier base would reduce vulnerability and ensure uninterrupted product availability.

Opportunities

The dental industry presents several opportunities for Remedent Inc to capitalize on. One notable opportunity is the growing demand for cosmetic dental procedures. With its expertise in providing aesthetic dental solutions, Remedent Inc can further penetrate this market segment and cater to the increasing number of individuals seeking cosmetic enhancements.

Furthermore, the rising adoption of digital technologies in dentistry opens doors for Remedent Inc to develop and market advanced dental software and devices. Aligning with this trend can lead to new revenue streams and a competitive edge in the industry.

Threats

Remedent Inc faces various threats that could impact its business operations. One significant threat is the intense competition within the dental industry. The presence of established and emerging competitors requires Remedent Inc to continuously enhance its offerings and maintain its competitive position.

Moreover, economic downturns and changing reimbursement policies can affect consumer spending on dental procedures, potentially reducing demand for Remedent Inc's products and services. Monitoring economic and policy changes is crucial to mitigate such threats.

Remedent Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Remedent historical P/E ratio, EBIT multiple, and P/S ratio

Remedent annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Remedent shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
20.00 M Stocks
Jan 1, 2018
20.00 M Stocks
Jan 1, 2019
20.00 M Stocks
Jan 1, 2020
20.00 M Stocks
Jan 1, 2021
20.00 M Stocks
Jan 1, 2022
20.00 M Stocks
Jan 1, 2023
20.00 M Stocks
Jan 1, 2024
20.00 M Stocks

Remedent stock splits

In Remedent's history, there have been no stock splits.
Price targets and forecasts for Remedent are not yet available.

Remedent Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/17/2010-0.03USD1.97 MUSD2010 Q3
11/17/2009-0.03USD-USD2010 Q2
8/14/2009-0.02USD3.74 MUSD2010 Q1
6/29/20090.00USD4.80 MUSD2009 Q4
11/19/2008-0.02USD2.69 MUSD2009 Q2
8/19/20080.00USD3.21 MUSD2009 Q1
7/15/2008-0.05USD2.28 MUSD2008 Q4
2/14/2008-0.04USD1.32 MUSD2008 Q3
11/19/2007-0.04USD1.03 MUSD2008 Q2
7/13/2007-0.01USD1.65 MUSD2007 Q4

Remedent shareholder structure

% Name
∞%
De Vreese (Guy)
De Vreese (Guy)
∞%
Sternberg (Stuart L)
Sternberg (Stuart L)
∞%
Kolsteeg (Frederick)
Kolsteeg (Frederick)

Remedent Executives and Management Board

PA

Mr. Philippe Van Acker

(55)

Chief Financial Officer, Chief Accounting Officer, Director · since 2005

Compensation192,758.00 USD
GV

Mr. Guy De Vreese

(65)

Chairman of the Board, Chief Executive Officer · since 2002

Compensation38,852.00 USD
FK

Mr. Fred Kolsteeg

(77)

Independent Director

Remedent Supply Chain

Remedent Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
Soundwill
Supplier
-0.31
-0.42
—
—
—

Frequently asked questions about Remedent

The business model of Remedent Inc. focuses on providing innovative dental solutions and products. Remedent Inc. is a leading global player in the dental industry, offering a range of advanced dental products, including the highly popular and successful GlamSmile veneer system. They aim to meet the increasing demand for aesthetic dental treatments by offering highly-effective, non-invasive solutions. With their cutting-edge technology and strategic partnerships, Remedent Inc. continues to revolutionize the dental industry and deliver exceptional results to patients worldwide.

All fundamentals and in-depth analysis of Remedent

Our stock analysis for Remedent stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Remedent. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Remedent Stock
Remedent Revenue→
Remedent Stock
Remedent Net Income→
Remedent Stock
Remedent P/E→
Remedent Stock
Remedent P/S→
Remedent Stock
Remedent EBIT→
Remedent Stock
Remedent Dividend→
Remedent Stock
Remedent Directors Dealings→
Remedent Stock
Remedent Stocks→
Remedent Stock
Remedent Market capitalization→
Remedent Stock
Remedent Debt→
Remedent Stock
Remedent Liabilities→
Remedent Stock
Remedent Equity→
Remedent Stock
Remedent AAQS→
Remedent Stock
Remedent Employees→
Remedent Stock
Remedent ROE→
Remedent Stock
Remedent ROA→
Remedent Stock
Remedent ROCE→
Remedent Stock
Remedent News→
Remedent Stock
Remedent Analyst Price Targets→

Health Stocks

RemeGen CoRemed CoRemeGen CoRelmada TherapeuticsREMSleep HoldingsRelay TherapeuticsRemus PharmaceuticalsRekah Pharmaceutical IndustryRenascienceRein TherapeuticsReNerveRegis HealthcareAll Stocks A–Z →